New reports on the markets for vascular grafts, including hemodialysis grafts, provide insights into this growing industry.
Grand View Research, based in San Francisco, reports that the global vascular grafts market was valued at $2.01 billion in 2019 and is expected to see a compound annual growth rate (CAGR) of 6.4% from 2019 to 2026. One caveat posits the estimate may be lower owing to “low reimbursement and high out-of-pocket expenditure in emerging economies.”
Overall the marketplace is divided into hemodialysis access grafts, peripheral vascular grafts, and endovascular stent grafts, the lattermost of which led the overall market in 2018. The peripheral vascular market is set to lead in 2019, Grand View notes.
That leaves hemodialysis access grafts. A report from a different source, Market Insights Reports of Harrisburg, NC, states that the global hemodialysis vascular grafts market is “likely to expand at a CAGR of 4.1%” over the period from 2019 to 2024. The global market size for hemodialysis vascular grafts was valued at $209.1 million in 2018, Grand View reports.
Grand View breaks down regional snapshots, with the United States accounting for more than 27% of global market revenue for hemodialysis vascular grafts. Europe represented about 24% of the total revenue in 2017. In the US, acceptance of synthetic hemodialysis vascular access grafts plus higher numbers of patients with kidney disease are boosting market growth.
Asia and other emerging markets will be key for hemodialysis vascular grafts, notes a report from OG Analysis, based in Manchester, CT.
The reports list several large players in the field: W.L. Gore & Associates (Newark DE); C.R. Bard, Inc. (Murray Hill, NJ); Terumo Medical Corporation (Somerset, NJ); LeMaitre Vascular, Inc. (Burlington, MA); and Getinge AB (Gothenburg, Sweden, with U.S. sales offices in Wayne, NJ, and Rochester, NY).
In addition to hemodialysis vascular grafts, arteriovenous fistulas also are in the news. Fistula innovations aim to make dialysis as streamlined and smooth as possible for patients. Recently a nephrologist created a minimally invasive fistula using two systems newly approved by the FDA—the Ellipsys System developed by Avenu Medical (San Juan Capistrano, CA) and the BD WavelinQ system developed by Becton Dickinson and Company (Franklin Lakes, NJ).
The BD WavelinQ nonsurgical procedure is performed by inserting flexible magnetic catheters into an artery and vein, according to Neghae Mawla, MD, an interventional nephrologist based in Plano, TX. The magnets align and the artery–vein connection is made via a burst of radiofrequency energy. With the BD WavelinQ, the physician can choose between two possible anatomical locations for the endoAVF. In the Ellipsys system, the connection is made via a single catheter inserted through the vein into the artery, followed by a fusion of the two vessels. The location of this connection provides a third access site, potentially allowing for another useable fistula and better outcomes.
